OR WAIT null SECS
April 05, 2024
Under a collaboration agreement, Lonza will manufacture sabirnetug, Acumen Pharmaceuticals' mAb in clinical development for treating Alzheimer’s disease.
April 04, 2024
Genmab's acquisition of ProfoundBio will boost its clinical and preclinical pipeline of ADCs for targeted cancer treatment.
The annual report details OPQ’s quality assurance work for 2023 including its support for the creation of guidance documents.
April 03, 2024
Our Future Health, a health research program in the UK, has welcomed Novartis as a new industry partner.
April 02, 2024
Plans to update the European Union’s variation framework have been finalized.
Carl Allenspach, director of business operations, manufacturing, science, and technology organization at Bristol Myers Squibb discusses the interactive and collaborative important of INTERPHEX.
The European pharma industry needs to be prepared for the new clinical data requirements.
April 01, 2024
Pharmaceutical Technology gives a brief overview of some of developments in manufacturing facilities, including news from W.R. Grace & Co, ITT Inc, and SMC.
March 30, 2024
The company is voluntarily recalling the product for potential super potent bottles due to overfilling.
FDA granted fast track designation to nipocalimab, which J&J is developing for helping alloimmunized pregnant adults treat FNAIT, a rare disease that poses risk to the fetus or newborn.